Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS

Inclusion Criteria: * The patient must sign voluntarily the informed consent from before any study test is conducted that is not part of routine patient care, with the knowledge that he/she can abandon the study at any time without this affecting his/her previous care. * Aged between 18 and 70. * Pathological diagnosis of non operable and/or metastatic soft tissue sarcoma. * The following histological subtypes can be included: * Undifferentiated pleomorphic sarcoma (previously,malignant fibrous istiocytoma) * Leiomyosarcoma * Angiosarcoma * Liposarcoma * Synovial sarcoma * Fibrosarcoma * Hemangiopericytoma * Neurofibrosarcoma * Mixofibrosarcoma * Unclassified sarcoma * Measurable disease, according to RECIST criteria * Performance status 0-2 Eastern Cooperative Oncology Group(ECOG). * Adequate bone marrow function (hemoglobin \> 10 g/dL, leukocytes ≥ 3.000/mm3, neutrophils ≥1.500/mm3, platelets ≥ 100.000/mm3). Patients with plasma creatinine ≤ 1,6 mg/dL, transaminases ≤2.5 times the upper limit of normal (ULN), total bilirubin ≤ upper limit of normal (ULN), CPK ≤ 2.5 times upper limit of normal (ULN), alkaline phosphatase ≤ 2.5 times the upper limit of normal (ULN) are acceptable. If the increase of alkaline phosphatase is \> 2.5 times the upper limit of normal (ULN), then the alkaline phosphatase liver fraction and/or 5' nucleotidase and/or GGT must be ≤ upper limit of normal (ULN). * Men or women of child bearing potential should be using an effective …